Valerio Therapeutics
C4X
Company Profile
Business description
Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using three proprietary platforms: the PlatON platform, DecoyTAC, and the V-Body platform, generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners. Its pipeline includes Metabolic Diseases, Immunology & Inflammatory.
Contact
49, Boulevard du General
Martial Valin
Paris75015
FRAT: +33 145587600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
41
Stocks News & Analysis
stocks
Big IPOs are enticing but are they good investments?
Historically, buzzy debuts have been painful for buyers.
stocks
This defensive ASX listed REIT offers a 5% yield
Solid outlook underpinned by rent uplifts and development pipeline.
stocks
Chart of the Week: Anthropic’s IPO range sits below our fair value
Our fair value is above the IPO range, but outcomes could differ widely.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,720.50 | 116.10 | -1.31% |
| CAC 40 | 8,080.74 | 66.09 | -0.81% |
| DAX 40 | 25,463.81 | 272.43 | -1.06% |
| Dow JONES (US) | 49,097.06 | 1,101.11 | -2.19% |
| FTSE 100 | 10,452.68 | 98.49 | -0.93% |
| HKSE | 22,841.62 | 453.13 | -1.95% |
| NASDAQ | 23,879.20 | 550.69 | -2.25% |
| Nikkei 225 | 58,215.98 | 1,228.23 | -2.07% |
| NZX 50 Index | 14,129.92 | 117.33 | -0.82% |
| S&P 500 | 7,175.83 | 147.80 | -2.02% |
| S&P/ASX 200 | 8,617.30 | 113.10 | -1.30% |
| SSE Composite Index | 3,577.62 | 10.21 | -0.28% |